Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

How To Save A Drug: Iressa’s Return Relied On Consistency Across Totality Of Evidence

Oct 26 2016

• By Bridget Silverman

Related Content

AstraZeneca's Iressa Use Narrowed: No New Commercial Patients

Jun 17 2005

Qiagen gets second therascreen CDx US approval as FDA OKs Iressa

Jul 14 2015

AstraZeneca’s <em>Iressa</em>, Now Resurrected, Faces Daunting U.S. EGFR Market

Jul 20 2015

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Oct 19 2016

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Oct 10 2016

First Blood-Based Lung Cancer EGFR Test Gets Green Light

Jun 02 2016

Iressa Reviewers

Oct 26 2016

Iressa Clinical Development Timeline

Oct 26 2016

FDA Continues To Speed PD-1/L1 Drugs To Market

Oct 25 2016

Related Companies

AstraZeneca PLC

Astellas Pharma, Inc.

Genentech, Inc.

Boehringer Ingelheim GmbH

Roche Holding AG

Qiagen NV

Eli Lilly and Company

Merck & Co., Inc.

Bristol Myers Squibb Company

Additional Topics

United States Review Pathway Regulation Drug Review Profile BioPharmaceutical Cancer

More from Drug Review Profiles

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window